Replies to post #242384 on Biotech Values

[DewDiligence]

AZN acquires LOGC for $2.07/sh cash—a 667% premium to Friday’s close (not a typo), but a 44% discount to LOGC’s 12-month high and a 79% discount to LOGC’s 2018 IPO price (#msg-144332035):

https://finance.yahoo.com/news/alexion-astrazeneca-rare-disease-acquire-111500187.html

The 667% premium is the highest I’ve ever seen for a biotech buyout. The nominal deal value is $70M.